Clinical features and management of children with primary ciliary dyskinesia in England

Bruna Rubbo1,2, Sunayna Best3, Robert Anthony Hirst4

  • 1School of Clinical and Experimental Medicine, Faculty of Medicine, University of Southampton, Southampton, UK.

Insights

Children with primary ciliary dyskinesia (PCD) in England show poorer lung function compared to cystic fibrosis (CF) patients. Lower BMI in PCD children correlates with reduced lung function, highlighting the importance of nutritional status in management.

Area of Science:

  • Pediatric Pulmonology
  • Rare Diseases
  • Genetics

Background:

  • Primary ciliary dyskinesia (PCD) is a rare genetic disorder affecting cilia function.
  • The National Health Service in England established a specialized service for children with PCD.
  • Understanding the health status and lung function of children with PCD is crucial for effective management.

Purpose of the Study:

  • To describe the health status of children managed by the English National Management PCD Service.
  • To compare the lung function of children with PCD to those with cystic fibrosis (CF).
  • To identify factors influencing lung function in children with PCD.

Main Methods:

  • Multi-center service evaluation of the National Management PCD Service in England.
  • Inclusion of 333 children with PCD reviewed in 2015.
  • Comparison of lung function data with 2970 children with CF from the CF Registry.

Main Results:

  • Children with PCD had significantly lower mean %predicted forced expiratory volume in one second (FEV1) (76.8%) compared to CF (85.0%).
  • Lower FEV1 was observed in PCD patients up to age 15 and correlated with lower body mass index (BMI).
  • Hearing impairment was common (approx. 50%), and 33% had positive respiratory cultures, frequently *Haemophilus influenzae*.

Conclusions:

  • Children with PCD in England exhibit worse lung function than those with CF.
  • Nutritional status, indicated by BMI, is a significant factor affecting lung function in PCD.
  • Further research, including randomized controlled trials, is needed to optimize PCD management strategies.
Abstract

Related Concept Videos

COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations01:19

Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

Chronic Obstructive Pulmonary Disease, or COPD, is a long-term condition marked by persistent and only partially reversible airflow limitation. It involves two overlapping conditions—chronic bronchitis and emphysema—which often co-appear but differ in dominant symptoms and underlying mechanisms.Chronic Bronchitis FeaturesChronic bronchitis presents with a persistent productive cough and thick, sometimes purulent mucus due to airway inflammation, enlarged mucus glands, and goblet cell...